Integrity Bio, a privately held biologics company based in Camarillo, named Michael Reilly as its new chief executive officer on Tuesday.

Reilly succeeds Byeong Chang, the company’s founder and owner. Chang will continue as chief scientific officer, according to a statement from the company.

“The timing is right to hand over the reins,” Chang said in a statement. “Having worked very closely together, I have tremendous trust and confidence in Michael and believe he is the right person to lead this next phase of our growth.”

Integrity Bio, which specializes in biologics formulation development and drug product manufacturing, also has a location in Thousand Oaks. The company has produced vaccines, antibodies, proteins and peptides for more than 150 pharmaceutical firms.

Reilly previously served as vice president of business development at Integrity, and held executive positions at Baxter BioScience and Amgen Inc. prior to that.

“It has been a real privilege for me to work with Integrity Bio over the last eight years, and I’m excited to take the helm now as we have some big things planned for the coming year and beyond,” Reilly said in a statement. “I share Byeong’s optimism for the firm’s bright future in this growing field.”